Informa Life Sciences’ Inaugural

Immunotherapies & Cancer Vaccines

Wednesday 5 – Thursday 6 December 2012, Sheraton Brussels Hotel, Brussels, Belgium

Bringing together industry and academia to maximise the immune response, optimise clinical development and boost commercial success of immunotherapies

25+ Speakers – 25+ Case Studies – 10+ Hours of Networking and Partnering Opportunities

KEYNOTE PRESENTATIONS INCLUDE:

Dr Bernard A. Fox, Chief, Molecular & Tumour Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, USA

Professor David W. Scott, Vice Chair for Research Department of Medicine, Uniformed Services University of Health Sciences, USA

Dr Alan Korman, Vice President, Discovery Research, Bristol Myers Squibb, USA

Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dendreon, USA

Find winning strategies to improve your immunotherapy development programme

• Hear the latest research driving immunotherapy development and new applications for increasing immune response: Updates and case studies from Dendreon, Bristol Myers Squibb, Merck, Vaccinogen and INSERM

• Discover which immunotherapy approaches are most effective and successful: 8 case studies covering active, passive and non-specific immunotherapy

• Generate the correct pre-clinical data to ensure successful development into the clinic: Data from Argos Therapeutics, Biothera, Janssen, Uniformed Services University of Health and more

• Establish efficient and cost-effective clinical trials with a dedicated session on reliable patient populations and immune monitoring techniques

• Work out the best delivery method for your immunotherapy with leading industry insight on local and nanodelivery

Maximise your time out of the office with these BRAND NEW training courses!

Pre-Conference Workshop W: Tuesday 4th December 2012
Clinical Trial Design: The Key to Success
Leaders: Dr John Trizzino, ImmunoVaccine, Canada
Dr Gary Wood, TVAX Biomedical, USA
Dr Charles A. Nicolette, Argos Therapeutics, USA
Dr David Edwards, Cancer Research UK, UK
Dr Thomas Felzmann, Activartis Biotech GmbH, Germany

Evening Seminar X: Wednesday 5th December 2012
Practical Advice on Successfully Filing IND Applications
Leader: Dr Michael Covington, Dendreon, USA

Post-Conference Workshop Y: Friday 7th December 2012
Antibodies: Targeted Therapy as an Immunomodulator
Leaders: Dr Alan Korman, Bristol Myers Squibb, USA & Dr Gary Starling, Abbott, USA

Register online: www.informa-ls.com/immunotherapies

Pre-Conference Workshop W: Tuesday 4th December 2012
Clinical Trial Design: The Key to Success
Leaders: Dr John Trizzino, ImmunoVaccine, Canada
Dr Gary Wood, TVAX Biomedical, USA
Dr Charles A. Nicolette, Argos Therapeutics, USA
Dr David Edwards, Cancer Research UK, UK
Dr Thomas Felzmann, Activartis Biotech GmbH, Germany

Evening Seminar X: Wednesday 5th December 2012
Practical Advice on Successfully Filing IND Applications
Leader: Dr Michael Covington, Dendreon, USA

Post-Conference Workshop Y: Friday 7th December 2012
Antibodies: Targeted Therapy as an Immunomodulator
Leaders: Dr Alan Korman, Bristol Myers Squibb, USA & Dr Gary Starling, Abbott, USA

Find winning strategies to improve your immunotherapy development programme

• Hear the latest research driving immunotherapy development and new applications for increasing immune response: Updates and case studies from Dendreon, Bristol Myers Squibb, Merck, Vaccinogen and INSERM

• Discover which immunotherapy approaches are most effective and successful: 8 case studies covering active, passive and non-specific immunotherapy

• Generate the correct pre-clinical data to ensure successful development into the clinic: Data from Argos Therapeutics, Biothera, Janssen, Uniformed Services University of Health and more

• Establish efficient and cost-effective clinical trials with a dedicated session on reliable patient populations and immune monitoring techniques

• Work out the best delivery method for your immunotherapy with leading industry insight on local and nanodelivery

Maximise your time out of the office with these BRAND NEW training courses!

Pre-Conference Workshop W: Tuesday 4th December 2012
Clinical Trial Design: The Key to Success
Leaders: Dr John Trizzino, ImmunoVaccine, Canada
Dr Gary Wood, TVAX Biomedical, USA
Dr Charles A. Nicolette, Argos Therapeutics, USA
Dr David Edwards, Cancer Research UK, UK
Dr Thomas Felzmann, Activartis Biotech GmbH, Germany

Evening Seminar X: Wednesday 5th December 2012
Practical Advice on Successfully Filing IND Applications
Leader: Dr Michael Covington, Dendreon, USA

Post-Conference Workshop Y: Friday 7th December 2012
Antibodies: Targeted Therapy as an Immunomodulator
Leaders: Dr Alan Korman, Bristol Myers Squibb, USA & Dr Gary Starling, Abbott, USA

Register online: www.informa-ls.com/immunotherapies
Immunotherapies & Cancer Vaccines 2012 provides a great opportunity to learn about the latest developments in the immunotherapy world from the people who are actually making it happen. Because it combines quality input and networking, this conference is not to be missed’

‘

**Clinical Trial Design: The Key to Success**

The recent success of therapies such as Ipilimumab and Sipuleucel have drawn investigators’ attention to the power of immunotherapy in the treatment of cancer. However, translating an idea to the clinic is fraught with difficulty. The purpose of this workshop will be to highlight some of these challenges.

- What constitutes cancer immunotherapy?
- What constitutes tumor immunology?
- What should the preclinical package look like?

**Workshop leaders:**

- **Dr John Tizzoni, CEO, ImmunoVaccine, Canada**
- **Dr Gary Wood, President & CEO, TVAX Biomedical, USA**
- **Dr Thomas Fellenbaum, CEO, Actavis Biotech GmbH, Germany**

**How do we translate the idea to the clinic?**

- What constitutes success in the clinic?
- How to enhance tumour response?
- What is the most appropriate patient population?

**Registration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be provided**

**DAY ONE: WEDNESDAY 5 DECEMBER 2012**

**08.00** Registration and Opening of the VIC Congress Exhibition Hall

**08.55** Chairperson’s Opening

**09.05** The Latest Development Updates on Provenge

Sipuleucel-T for prostate cancer: Development of the first approved active immunotherapy

**09.35** The Latest Updates on the Improvements to Ipilimumab

The latest developments in improving Yervoy, and CTLA-4 and PD-1

**10.05** Potential molecular pathways to modulate for the success of immunotherapy

This presentation will discuss pathways to break tolerance (adjuvants and co-stimulations) to overcome immune-inergy and molecules that block immunosuppressive pathways. These may help us understand our triggers and toxins and their effects on tumour embryo activity.

**10.35** Morning Coffee and Poster/Exhibition Viewing Time

**11.05** Keynote Presentation

The impact of genomic sequencing data in cancer immunotherapy

At the cellular level it is clear that cancer is a genetic disease arising as a clone that expands and grows in an unregulated manner. While it has always been presumed that neoplasia is a consequence of these clones, only in the past few years has the mechanism begun to show diversity of these mutations been elucidated by modern DNA sequencing technology. Immunotherapy is the premier biological approach to targeted therapy. This presentation will discuss the consequences of this new knowledge of tumour cell biology to the immunotherapeutic approach to treating cancer.

**11.35** Bladder cancer: Lessons from 35 years of a clinical immunotherapy

To find out more information about this presentation, please visit the conference website at www.immunotherapies.com/immunotherapies.

**11.50** Novel Approaches for Maximising Immune Response

**12.05** Biomarker-guided development of cancer vaccines and combination therapies

Immunotherapy development is complex requiring rational selection and combination of the right antigens, immunomodulators, standard of care and patient population. In this presentation – using two novel peptide-based cancer immunotherapy candidates for treatment of renal cell cancer (IMM401) and colorectal cancer (IMM401) – we will discuss the use of novel pharmacodynamic and prognostic/predictive biomarkers to rationally guide clinical development of immunotherapy combinations will be discussed.

**12.20** Lunch and parking time

**13.35** Immunostimulatory therapies: Immunocytokines/Cancer vaccines

To find out more information about this presentation, please visit the conference website at www.immunotherapies.com/immunotherapies.

**13.50** Professor Sonia Quarantino, Senior Medical Director and Immunology Advisor, Merck Serono, Germany

**14.05** Novel monoclonal antibody therapeutic for Alzheimer’s disease

Amyloid precursor protein (APP) is a primary molecule in AD pathogenesis. We employ a MAB (BBS) that binds to the BACE cleavage site on cell-surface APP. Transgenic AD mice treated with BBS MAB compared to control MAB showed significant reductions in intra- and extra-cellular Aβ, significantly improved performance in behavioral tests to the same level as that of non-transgenic mice, and reduced levels of Aβ42 indicating improved safety. The rapid cellular internalisation of the MAB after binding to APP may be beneficial for avoiding microglia and complement activation that have been reported for anti-Ab All that cut to amyloid plaques. The BBS MAB is a strong candidate for clinical development.

**14.35** Immunologic mechanisms driving the combinatorial activity of elotuzumab and lenalidomide in multiple myeloma models

Elotuzumab, a humanised monoclonal antibody, has shown promise as a combination partner of lenalidomide/dexamethasone for the treatment of relapsed or refractory Multiple Myeloma. Randomised Phase 3 clinical studies are underway to examine the effect of elotuzumab in combination with lenalidomide on progression-free survival in newly diagnosed and relapsed/refractory MM patients. The immunologic mechanisms underlying the combinatorial activity have been dissected in xenograft models in vivo and in vitro using a co-culture system consisting of peripheral blood lymphocytes and Myeloma cell lines.

**15.05** Perspectives on T cell therapy for treatment of melanoma; a successful combination of chemotheraphy and immunotherapy

T-cell therapy is a very promising new strategy for treatment of metastatic melanoma and a fascinating example of successful combination of immunotherapy and chemotherapy. Tumor infiltrating lymphocytes (TIL) can be isolated from surgical removed tumour lesion and extensively expanded in vitro. TIL-based therapy is given in three phases; conditioning high dose chemotherapy, TIL infusion, and high dose IL-2. Immunodiagnostic responses seem probably with curative potential. New perspectives on this therapy will be discussed.

**15.35** Afternoon Tea and Poster/Exhibition Viewing Time

**16.05** A novel approach to cancer immunotherapy combining cancer cell vaccination and killer T cells

Research suggests that an efficacious immunotherapeutic strategy should involve significant T cell mediated cancer killing. We have developed a cancer immunotherapy platform that combines cancer cell vaccination and intravenous infusion of ex vivo-activated killer T cells to produce significant T cell mediated cancer killing. We will discuss results of our research demonstrating the therapeutic benefits that can be achieved with this strategy.

**16.35** Harnessing the power of the graft vs. tumour effect of non-myeloablative allogeneic stem cell transplants to enhance the effectiveness of cancer vaccine strategies

The immune mechanisms of haematopoietic allogeneic stem cell transplantation, called the graft vs. tumour (GVT) effect, has been shown capable of debulking chemotherapy-resistant disease in both xenogen and syngeneic mouse models. The GVT effect is less efficient in human allogeneic stem cell transplantation. However, the use of a powerful mechanism has been limited by the severe and often life-threatening side-effects, called graft vs. host disease (GVHD), that is intimately coupled to, and necessary for, the GVT mechanism. A novel biomolecular allergoid, called AllO²TM, has been developed that is designed to elicit an autologous GVT effect without GVHD toxicity.

**17.05** Therapeutic vaccination to fight cancers and chronic infectious diseases: Phase II clinical trials using posvarib MAbs-based vaccines

It is becoming increasing clear that a better understanding of immune mechanisms underlying the development of cancers and those associated with establishment of chronic infections are shared (e.g. presence and role of regulatory T cells, CD4+CD25+ Treg). A new therapeutic route has been developed called called graft vs. host type (GVH) that is intimately coupled to, and necessary for, the GVT mechanism. A novel biomolecular allergoid, called AllO²TM, has been developed that is designed to elicit an autologous GVT effect without GVHD toxicity.

**17.35** Proof of concept of therapeutic vaccine in the treatment of auto-immune disease: Anti-TNF in Crohn’s disease and anti-INF in lupus

To find out more information about this presentation, please visit the conference website at www.immunotherapies.com/immunotherapies.

**18.05** Closing Remarks from the Chairperson and End of Day One

**EVENING SEMINAR: WEDNESDAY 5TH DECEMBER 2012**

**Practical Advice on Successfully Filing IND Applications**

**Registration 18.15 – Start 18.30 – Networking, Dinner and refreshments will be provided**

**Workshop leader:** Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dundee, USA

**What will be discussed?**

- Considerations for various disease targets
- Key regulatory requirements - practical insight
- Insight into preclinical data required

**Free with a 4 day pass**

This interactive seminar provides the essential platform for industry professionals to understand how to best overcome the major regulatory hurdles when submitting an IND application. It is designed for those who are ready to take their project to the next stage.

**Workshop leader:** Dr Michael Covington, CMC Senior Director, Regulatory Affairs, Dundee, USA

**What is an IND application?**

- The most effective & successful IND applications

**To Register**

Tel: (+44) (0)20 7017 7481

Email: registrations@informa-ls.com

Web: www.informa-ls.com/immunotherapies

Please Quote: CQ3486
DAY TWO: THURSDAY 6 DECEMBER 2012

08.50 Chairperson’s Opening Remarks

Pre-Clinical Trial Assessment and Immune Modulation

KEYNOTE PRESENTATION
9.00 The changing regulatory landscape for immunotherapies & cancer vaccines
The recent approvals of a vaccine to treat prostate cancer and an immune-modulatory antibody for malignant melanoma have laid the foundation for the clinical specialty of immuno-oncology.

10.00 Case study: key updates on Janusen’s bupenuzumab programme
This presentation will discuss the latest information on the bupenuzumab programme as well as broader discussions on immunotherapy in neurogeneration with the example of Abeta immunotherapies.

11.00 Morning Coffee and Poster/Exhibition Viewing Time

11.30 Human immune system heterogeneity: impact on translating preclinical models to the clinic for immunotherapies
To find out more information about this presentation, please visit the conference website at www.informa-ls.com/immunotherapies

12.00 Immune modulators: Comparing the performance of different known immune modulators
• Overcoming the lack of systematically generated data, especially in humans
• How to best design an effective immunotherapy regimen

12.30 Preclinical development of cancer vaccines: obstacle and hurdles
This presentation will discuss the challenges and opportunities of efficacy models, as well as what extent safety needs to be monitored.

13.00 Lunch and partnering time

Designing Appropriate and Successful Clinical Trials

14.00 The changing regulatory landscape for immunotherapies & cancer vaccines
The recent approvals of a vaccine to treat prostate cancer and an immune-modulatory antibody for malignant melanoma have laid the foundation for the clinical specialty of immuno-oncology.

15.00 Immunotherapeutic strategies overcoming immunosuppression in the tumour microenvironment
Insufficient anti-tumour reactivity is due to the chronic inflammation represented by infiltrating leukocytes and soluble mediators leading to cancer progression. Using ret transgenic mouse melanoma model that mimics human melanoma, we demonstrated increased levels of chronic inflammatory factors and immunosuppressive factors in melanoma lesions correlated with tumor progression. Inhibitors of immunosuppressive tumour microenvironment induced anti-tumour effects and should be applied together with other melanoma immunotherapies.

16.00 Delivery Systems for Administering Immunotherapies
A local immunotherapy approach for the treatment of peritoneal metastases of gynaecological and gastrointestinal cancers
This presentation describes the clinical development of EGEN-001, a novel immunotherapy for local treatment of cancers that are metastasised to the peritoneal cavity. EGEN-001 is composed of an IL-12 plasmid and a novel lipopolymer delivery system and is designed to produce sustained local increases in IL-12 concentrations to stimulate the immune system against metastases without causing systemic toxicity.

17.00 Rational design of targeted Synthetic Vaccine Particles (SVP) for cancer
Selecta Biosciences is a clinical stage company developing targeted Synthetic Vaccine Particles (SVP). A modular and self-assembling manufacturing process allows rapid optimisation of antigen/antigen combinations. The SVP technology enables the use of potent adjuvants and reduces the burden of delivery.

17.30 Closing Remarks from the Chairperson and End of Conference

Antibodies: Targeted Therapy as an Immunomodulator

Registration 08.30 – Start 09.00 – End 15.30 – Workshop material, refreshments and lunch will be provided

There are a variety of different immunotherapy approaches that are being explored by industry and academia at present, however with antibodies being the most successful immunomodulator targeted therapy to date, this approach is what many companies are looking into closely. This interactive and case study led workshop explores current antibody immunotherapy products on the market, how they work, what led to their success and how this approach compares to other immunotherapy products.

Workshop leaders: Dr Gary Starling, Director, Oncology Biologics, Abbott Biotherapeutics, USA & Dr Alan Korman, Vice President, Discovery Research, Bristol Myers Squibb, USA

Topics to be discussed:
• Potential antibodies
• How to determine one modality from another
• Clinical settings applicable for antibody use
• Comparisons to cytokines
• Determining the best combination of antibodies

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

AT THE VIC CONGRESS 2012

Infoma’s Immunotherapies & Cancer Vaccines conference brings together key decision makers from across regulatory, technical, research and strategic departments and is the ideal platform for showcasing your latest technologies and services.

Reasons why you should choose this event:
• 4 audiences for the price of 1: Immunotherapies & Cancer Vaccines, Vaccine Manufacturing, Veterinary Vaccines and Cell Therapy Manufacturing
• Partner with 200+ senior level scientists at the VIC Congress with the authority to purchase new instruments, services and products

For further information on sponsorship & exhibitions opportunities, please contact:
Ben Edwards: Tel: +44 (0) 20 7017 4474 Email: ben.edwards@informa.com
Step 1. Select your workshops

- Pre-conference Workshop W: Clinical Trial Design: The Key to Success
- Evening Seminar X: Practical Advice on Successfully Filing IND Applications

Step 2. Select your pass

<table>
<thead>
<tr>
<th>Pass</th>
<th>Code</th>
<th>Book Before Friday 14th September 2012</th>
<th>Save</th>
<th>Book Between Friday 14th September and Friday 2nd November 2012</th>
<th>Save</th>
<th>Book After Friday 2nd November 2012</th>
<th>Save</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Day Pass: Conference Only</td>
<td>CQ3486C</td>
<td>£1459 + VAT @ 21% = £1813.79</td>
<td>£200</td>
<td>£1599 + VAT @ 21% = £1934.79</td>
<td>£100</td>
<td>£1699 + VAT @ 21% = £2055.79</td>
<td>£100</td>
</tr>
<tr>
<td>2 Day Pass: Conference + Evening Seminar</td>
<td>CQ3486CX</td>
<td>£1958 + VAT @ 21% = £2417.58</td>
<td>£200</td>
<td>£2098 + VAT @ 21% = £2538.58</td>
<td>£100</td>
<td>£2198 + VAT @ 21% = £2659.58</td>
<td>£100</td>
</tr>
<tr>
<td>3 Day Pass: Conference + Pre or Post Con Workshop</td>
<td>CQ3486CWY</td>
<td>£2199 + VAT @ 21% = £2660.79</td>
<td>£200</td>
<td>£2299 + VAT @ 21% = £2781.79</td>
<td>£100</td>
<td>£2399 + VAT @ 21% = £2902.79</td>
<td>£100</td>
</tr>
<tr>
<td>3 Day Pass: Conference + Pre or Post Con Workshop + Evening Seminar</td>
<td>CQ3486CWXY</td>
<td>£2598 + VAT @ 21% = £3143.58</td>
<td>£300</td>
<td>£2698 + VAT @ 21% = £3264.58</td>
<td>£200</td>
<td>£2798 + VAT @ 21% = £3385.58</td>
<td>£200</td>
</tr>
<tr>
<td>FULL Pass: Conference + Pre &amp; Post Con Workshop + FREE Evening Seminar</td>
<td>CQ3486CWXY</td>
<td>£2899 + VAT @ 21% = £3507.79</td>
<td>£700</td>
<td>£2999 + VAT @ 21% = £3628.79</td>
<td>£600</td>
<td>£3099 + VAT @ 21% = £3749.79</td>
<td>£600</td>
</tr>
</tbody>
</table>

The VAT rate is subject to change and may differ from the advertised rate. The amount you are charged will be determined when your invoice is raised.

DELEGATE DETAILS – Please photocopy form for multiple bookings!

(Mr/Mrs/Ms/Miss/Dr) Family Name
Forename
Job Title
Any special requirements?

Head of Department:
E-mail
Tel
Fax
Booking Contact:
E-mail
Tel
Fax
Name of Company/Department

Venue Details:
Sheraton Brussels Hotel
Place Rogier 3, Brussels, 1210 - Belgium
Phone: +32 2 2243111 Fax: +32 2 2243456
Web: www.sheratonbrussels.com

Reduced rate accommodation:
The cost of accommodation is not included in the conference fee. In order to book reduced rate accommodation please visit the section “Accommodation” on the event website www.informa-ls.com/immunotherapies. Please book early to avoid disappointment (discounted rates at the Sheraton Brussels Hotel are available only until 3rd November 2012 and are subject to availability).

Terms and Conditions
FEE: This includes all technical sessions, lunch and documentation.
CANCELLATIONS: Cancellations received in writing before and on Tuesday 20th November 2012 will be subject to a service charge of £99. The full conference fees remain payable after Tuesday 20th November 2012. Substitutions are welcome at any time. It may be necessary for reasons beyond the control of the organiser to alter the content and timing of the programme or the identity of the speakers. In the unfortunate event that an event is cancelled Informa are not liable for any costs incurred by delegates in connection with their attendance. This contract is subject to English Law.
ARE YOU REGISTERED?: You will always receive an acknowledgement of your booking. If you do not receive anything, please call us on +44(0) 20 7017 7481 to make sure we have received your booking.

Yes I agree to the terms and conditions as stated on this form.

DATA PROTECTION: The personal information shown on this form, and/or provided by you, will be held on a database and may be shared with other companies in the Informa Group in the UK and internationally. If you do not wish your details to be available to companies in the Informa Group please contact the Database Manager at the above address:
Tel: +44(0) 20 7017 7077, Fax: +44(0) 20 7017 7828 or email: integrity@informa.com - quoting the reference number printed on the mailing label.

INCORRECT MAILING: If you are receiving multiple mailings or you would like us to change any details or remove your name from our database, please contact the Database Manager at the above address, Tel: +44(0) 20 7017 7077, Fax: +44(0) 20 7017 7828 or email: integrity@informa.com - quoting the reference number printed on the mailing label.

ANY SPECIAL REQUIREMENTS: Please inform us if you have any special requirements by calling Customer Services on +44(0) 20 7017 7481.

Are we mailing you correctly? To update your contact details on our database please email integrity@informa.com